Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02106195 · ClinicalTrials.gov registry record · Phase 2
A Safety and Tolerability Study of Belumosudil (KD025) Treatment in Subjects With Moderately Severe Psoriasis Vulgaris
A Phase 2 study, sponsored by Kadmon Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT02106195 is a Phase 2 study that has completed, run by Kadmon Corporation. The registered enrollment target is 8 participants.
The verdict
NCT02106195, a Phase 2 study, has completed, sponsored by Kadmon Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
The primary objective is to assess the safety and tolerability of 200 mg of belumosudil administered orally once daily for 28 days.
Interventions
- DRUG Belumosudil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2014-04 |
| Est. Completion | 2014-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02106195
The ClinicalTrials.gov registry entry for NCT02106195 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kadmon Corporation, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Belumosudil is the first listed.
NCT02106195 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02106195 about?
NCT02106195 is a clinical study titled "A Safety and Tolerability Study of Belumosudil (KD025) Treatment in Subjects With Moderately Severe Psoriasis Vulgaris". The primary objective is to assess the safety and tolerability of 200 mg of belumosudil administered orally once daily for 28 days.
What is the current status of trial NCT02106195?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2014-04. Estimated completion is 2014-09.
What interventions are being tested in trial NCT02106195?
The interventions under investigation include: Belumosudil (DRUG).
Who is sponsoring clinical trial NCT02106195?
This trial is sponsored by Kadmon Corporation, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.